US 12,459,992 B2
Methods for treatment of refractory generalized myasthenia gravis
Camille Bedrosian, Woodbridge, CT (US); Fanny O'Brien, Norwell, MA (US); and Jing Jing Wang, Woodbridge, CT (US)
Assigned to Alexion Pharmaceuticals, Inc., Boston, MA (US)
Filed by ALEXION PHARMACEUTICALS, INC., Boston, MA (US)
Filed on Jan. 15, 2021, as Appl. No. 17/150,005.
Application 17/150,005 is a continuation of application No. 15/595,890, filed on May 15, 2017, abandoned.
Claims priority of provisional application 62/500,643, filed on May 3, 2017.
Claims priority of provisional application 62/489,240, filed on Apr. 24, 2017.
Claims priority of provisional application 62/346,168, filed on Jun. 6, 2016.
Claims priority of provisional application 62/342,321, filed on May 27, 2016.
Prior Publication US 2021/0246196 A1, Aug. 12, 2021
Int. Cl. C07K 16/18 (2006.01); A61K 39/00 (2006.01); A61M 1/34 (2006.01)
CPC C07K 16/18 (2013.01) [A61M 1/3496 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55 (2013.01); C07K 2317/24 (2013.01)] 15 Claims
 
1. A method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering a therapeutically effective amount of an eculizumab variant comprising a heavy chain amino acid sequence according to SEQ ID NO: 14 and a light chain amino acid sequence according to SEQ ID NO: 11 to the patient;
wherein the patient is positive for auto-antibodies binding to nicotinic acetylcholine receptor (anti-AChR); and
wherein the patient is administered the eculizumab variant for at least 26 weeks.